Tucotuzumab celmoleukin

Synonyms: EMD 273066; huKS-IL2
Tucotuzumab celmoleukin (EMD 273066) 是一种由针对人 EpCAM 抗原的 IgG1 单克隆抗体和两分子 IL2 组成的免疫细胞因子,可结合 EpCAM,与射频消融协同对结肠腺癌发挥抗肿瘤作用,并可用于结肠腺癌和结肠癌的相关研究。
产品编号: MS-B21540 纯度: 98.797% CAS No.: 339986-90-2
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价

产品描述

Tucotuzumab celmoleukin (EMD 273066) 是一种由针对人 EpCAM 抗原的 IgG1 单克隆抗体和两分子 IL2 组成的免疫细胞因子,可结合 EpCAM,与射频消融协同对结肠腺癌发挥抗肿瘤作用,并可用于结肠腺癌和结肠癌的相关研究。

生物实验数据

生物活性 Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine composed of an IgG1 monoclonal antibody targeting the human EpCAM antigen and two molecules of IL2 that binds EpCAM, exerts antitumor effects against colon adenocarcinoma synergistically with radiofrequency ablation, and can be used in research related to colon adenocarcinoma and colon cancer.
IC50 & Target

IL-2

 

体内研究
(In Vivo)

Tucotuzumab celmoleukin (15-37.5 μg;气管内给予;每日 1 次,连续 5 天或给 2 次) 单处理可中度抑制 BALB/c 小鼠体内 CT26-KS 结肠腺癌的生长;当与部分射频消融 (RFA) 联合使用时,可诱导协同性肿瘤生长抑制作用。

Animal Model: BALB/c (6- to 8-wk-old female; injected s.c. with 5×105 CT26-KS colon adenocarcinoma cells in the abdomen)
Dosage: 15 μg (subtherapeutic single agent; combination therapy); 37.5 μg (combination therapy)
Administration: i.t.; daily for 5 days (15 μg); 2 doses (37.5 μg)
Result: Resulted in moderate tumor growth suppression compared with no treatment (P = 0.002), but no complete tumor resolution when used alone with subtherapeutic dosing (15 μg i.t.
days 11-15).
Achieved synergistic tumor growth suppression (P < 0.001 on day 16 and P < 0.002 on day 19 versus all other groups), complete tumor resolution in 8 of 16 mice, and significantly enhanced survival compared with untreated mice (P < 0.001), RFA alone (P < 0.001), or Tucotuzumab celmoleukin alone (P = 0.002) when combined with partial RFA.
Across all experiments, combination therapy resulted in complete tumor resolution in 14 of 28 mice (P < 0.001 versus no treatment, P = 0.024 versus RFA alone, P = 0.003 versus Tucotuzumab celmoleukin alone).
Showed tumor growth suppression not significantly different from the 5-day 15 μg dose regimen, and both were superior to RFA alone (P < 0.005 on day 25) when given as two 37.5 μg i.t.
doses (days 10 and 14) in combination with RFA.
Resulted in complete resolution of the treated abdominal tumor in 7 of 15 mice and complete resolution of the untreated distant flank tumor in 8 of 15 mice as a single agent (15 μg i.t.
days 10-14).
Enabled tumor-free mice treated alone or in combination with RFA to reject rechallenges with CT26-KS tumor cells, and 3 of 3 mice treated alone to reject parental CT26 tumor rechallenges.
Induced 3% of CD4+ T cells and 5-6% of CD8+ T cells expressing IFN-γ after in vitro stimulation with CT26-KS cells in splenocytes from mice treated alone, with similar low proportions expressing GM-CSF.
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT00408967EMD Serono
Ovarian Cancer
2006-12-31PHASE2
NCT00132522EMD Serono
Ovarian Cancer|Colorectal Cancer|Carcinoma, Non-small-cell Lung|Prostate Cancer
2005-05PHASE1
NCT00016237EMD Serono|National Cancer Institute (NCI)|Memorial Sloan Kettering Cancer Center
Bladder Cancer|Kidney Cancer|Lung Cancer
2000-12PHASE1
性状 液体
颜色 Colorless to light yellow

化学信息

CAS No. 339986-90-2
别名 EMD 273066; huKS-IL2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础